Ticaren 60 mg (Ticagrelor)

Adult dose

Do not use this medicine in combination with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation of this medicine is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Patients who took 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. - Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). - The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Refer to the dosage and administration for patients with acute coronary syndrome. - Data on the safety and efficacy of this medicine for use exceeding 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. Method of administration This medicine is administered orally and may be taken with or without food. Patients who have difficulty swallowing the tablets should crush this medicine into a fine powder, disperse it in half a glass of water, and drink it immediately; rinse the glass with half a glass of water and drink again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medication. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. Patients with renal impairment No dose adjustment is necessary in patients with renal impairment. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy have not been established in pediatric patients under 18 years of age (see the ‘Other’ section).

This medication helps prevent platelets in the blood from clumping together to form clots, thereby reducing the risk of cardiovascular diseases such as myocardial infarction or stroke. However, this medication may increase the risk of bleeding; therefore, it should not be used in patients who have active bleeding or a history of intracranial hemorrhage. Patients scheduled for surgery should discontinue this medication at least 5 days prior to the procedure and report any bleeding symptoms to medical personnel immediately. Patients with hypersensitivity to this medication, severe liver impairment, or those taking strong CYP3A4 inhibitors such as certain antibiotics or antivirals should not use this medication. Patients at high risk for bleeding should use this medication cautiously, particularly when taken together with drugs that increase the risk of bleeding, such as non-steroidal anti-inflammatory drugs, anticoagulants, or high-dose aspirin. Patients at risk of bradycardia (slowed heart rate) or with a history of dyspnea should carefully monitor for any worsening of symptoms while taking this medication. This medication is not recommended during pregnancy, and breastfeeding women should consult with their doctor about discontinuing either breastfeeding or the medication. In case of overdose, the risk of bleeding may increase, so immediate medical assistance should be sought; specific antidotes are not available, and treatment should be symptomatic. During treatment with this medication, dizziness or confusion may occur, so caution is advised when driving or operating machinery. There may be potential interactions with other medications taken concurrently, so all medications should be disclosed to healthcare providers, particularly those that impact CYP3A4 or heart rhythm.

Hemorrhage, intracranial hemorrhage, ocular hemorrhage, ear bleeding, hypotension, dyspnea, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, dyspepsia, constipation, retroperitoneal hemorrhage, skin hemorrhage, rash, itching, muscle hemorrhage, urinary tract hemorrhage, genital hemorrhage, post-procedural bleeding, traumatic bleeding, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, thrombosis, deep vein thrombosis, cardiac thrombus, thrombocytopenia, hematoma, cerebral hemorrhage, confusion, dizziness, syncope, headache, vertigo, elevated serum creatinine, chest pain, pulmonary hemorrhage, pharyngitis, upper respiratory infection, asthma, pleural effusion, bronchitis, pneumothorax, pneumonia, pulmonary edema, muscle weakness, anaphylactic shock, thrombosis, thrombocythemia, spinal stenosis, dementia, migraine, paralysis, gait disturbance, rectal bleeding, anal bleeding, appendicitis, tendinopathy, bursitis, rhabdomyolysis, diabetes mellitus, hyperkalemia, hyperglycemia, hepatitis, snoring, aneurysm, heart failure, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, ventricular fibrillation, urinary tract infection, kidney stones, cerebral ischemia, venous stenosis, cerebral infarction, arterial stenosis, angina, coronary thrombosis, myocardial ischemia, fungal infection, anemia, vestibular disorder, malignant neoplasm of male genital organs, chemical poisoning, post-procedural hematoma, laceration, road traffic accident, trauma, oral edema, influenza-like illness, tuberculosis infection, hyperthermia, unspecified hernia, dyspnea, generalized edema, speech disorder, cerebral hypoxia, scalp tenderness, peripheral neuropathy, neck stiffness, speech difficulties, seizures, neuropathy, neuralgia, movement disorders, tremors, lower limb paralysis, coma, sensory loss, oral pain, gastroenteritis, belching, irritable bowel syndrome, stomatitis, ulcerative stomatitis, benign gastrointestinal neoplasm, dental disease, tongue disease, tendinitis, arthrosis, chondrocalcinosis, spinal osteoarthritis, arthritis, contact dermatitis, fungal dermatitis, erythematous rash, hyperkeratosis, acute urticaria, onychomycosis, hair loss, scleroderma, dermatofibroma, increased sweating, hypokalemia, hypocalcemia, unspecified lipid metabolism disorder, hyperkalemia, hypomagnesemia, hypoglycemia, elevated AST, elevated ALT, insomnia, anxiety, memory disturbance, erectile dysfunction, agitation, orthostatic hypotension, worsening hypertension, cyanosis, atrial fibrillation, atrial arrhythmia, complete atrioventricular block, frequent urination, dysuria, urinary retention, conjunctival hyperemia, ocular pain, visual disturbances, tinnitus, ear pain, lymphadenopathy, eosinophilia, leukocytosis, sexual dysfunction, prostate enlargement, ovarian cyst, amenorrhea, vaginitis, loss of taste, altered smell, increased TSH, hypothyroidism, injection site reaction, injection site pain, palpitations, bradycardia, atrial fibrillation

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The recommended storage temperature is room temperature between 1 degree and 30 degrees Celsius.

Appearance

Pink, bilayer convex circular film-coated tablet

Package unit

60 tablets/box [10 tablets/PTP x 6]